ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2022

Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.

Carlen A Yuen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.